Ioannis Rabias
Head of QC Hellenic Pasteur Institute
Seminars
Thursday 18th February 2027
Leveraging Established mRNA Vaccine Quality Standards to Guide the Transition into Emerging mRNA Therapeutics
3:30 pm
- Distinguishing drug-substance CQAs from drug-product CQAs to clarify where controls need to be applied
- Setting phase-appropriate specifications that evolve from Phase I through later-stage development
- Determining what level of heterogeneity is acceptable without compromising safety, potency or manufacturability
